Arzerra, Rituxan Get New Black Box Warnings For Hepatitis B Reactivation

Arzerra, Rituxan Get New Black Box Warnings For Hepatitis B Reactivation

SILVER SPRING, Md. - The Food and Drug Administration on Sept. 25 said it has approved new boxed warnings for the immune-suppressing and anti-cancer drugs Arzerra and Rituxan because of the risk that they might reactivate the hepatitis B virus in patients.

Find full version on lexis Advance®
Access this news story on lexis.com®